Contact this trialFirst, we need to learn more about you.
MAPK Inhibitor
MAPK Inhibitors + Anti-PD1 Therapy for Brain Tumors
Recruiting1 awardPhase 1 & 2
Washington DC, District of Columbia
This trial combines two types of treatments, MAPK inhibitors and anti-PD1 therapy, to treat certain types of pediatric brain tumors that have specific genetic alterations. The goal is to improve the immune response
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.